PHILADELPHIA and LONDON, April 30 /PRNewswire-FirstCall/ --
GlaxoSmithKline (NYSE: GSK) today announced a number of changes to its
Corporate Executive management team. In a message to employees, Andrew
Witty, CEO designate, detailed new appointments and his new management team
which will take effect on May 22nd when he assumes the role of Chief
Executive Officer.
Outlining the context for these changes, Andrew Witty said: "It is
clear that our industry is facing a rapidly changing environment. Demand
for innovative medicines and healthcare products continues to grow, however
we are also presented with increasing challenges, such as cost containment,
regulatory pressures and generic competition."
To address these challenges, Witty stated that the company must work
hard to increase GSK's global reach and presence, and ensure that vaccines,
consumer healthcare and pharmaceuticals all play their full potential. He
emphasized the need for GSK's business regions to drive sales growth, and
announced new operational structures to expand and improve GSK's
capability, particularly in emerging markets and in Asia.
"Emerging markets, such as Brazil, Russia, India, China and the Middle
East, are significant growth drivers of the future. They are already
contributing close to 25% of today's market growth and are forecast to grow
even faster in the future, around triple the rate of western countries. It
is essential that we have an operating structure that is dynamic and
responsive to the opportunities in these markets," said Witty.
"I am therefore creating a new Emerging Markets region which will
ensure that we devote the focus required to build on our excellent
foundations in those markets and truly establish ourselves as a trusted,
long-term partner, one that is actively working to address the specific
healthcare needs in those countries," he said.
A new Asia Pacific region will also be created, which includes Japan
and Australia. Witty noted that many of these countries have sophisticated
and well-organized healthcare systems and that these markets represent
"significant and immediate opportunities" for existing products and
products which will be launched over the next few years.
As part of the changes to business regions, GSK has also realigned
markets in North America (combining the US, Canadian and Puerto Rican
businesses) and has established new operational areas in Europe to maximize
their potential and opportunities for growth.
Witty also placed emphasis on the development of GSK's business through
partnership and collaboration, and announced a new dedicated team for
Corporate Strategy and Development:
"Making the changes required to develop our business for the next
decade requires a rigorous and disciplined focus on corporate strategy. A
key element of this new team's remit will be to proactively seek new
business opportunities to expand our global reach and drive sales growth,"
he said. Finally, Witty also spoke to measures to improve processes and
ensure that the company works effectively and efficiently. He also placed
great emphasis on the need to sustain and develop the strong ethical
culture of GSK:
"Ultimately, our culture and our people will be the key factors in our
success. We need to ensure that we always do what is right for the patients
and I want GSK to meet the highest standards expected of us by society,"
said Witty.
GSK Corporate Executive Team (effective May 22nd 2008):
-- Andrew Witty, Chief Executive Officer*
-- Julian Heslop, Chief Financial Officer*
-- Moncef Slaoui, Chairman, Research & Development*
-- Chris Viehbacher, President, North American Pharmaceuticals*
-- Simon Bicknell, SVP, Company Secretary & Compliance Officer
-- John Clarke, President, Consumer Healthcare
-- Marc Dunoyer, President, Asia Pacific
-- Eddie Gray, President, Pharmaceuticals Europe
-- Abbas Hussain, President, Emerging Markets. Abbas will join GSK on 2
June from Eli Lilly and Company, where he has spent 20 years overseeing
markets throughout Europe, Africa/Middle East and Australasia
-- Duncan Learmouth, SVP, Corporate Communications & Global Community
Partnerships
-- Bill Louv, Chief Information Officer
-- Dan Phelan, Chief of Staff
-- David Pulman, President, Global Manufacturing & Supply
-- David Redfern, Chief Strategy Officer
-- Jean Stephenne, President and General Manager, Biologicals
-- Claire Thomas, SVP, Human Resources
-- SVP & General Counsel (currently vacant)
* Executive directors who are also members of GSK's Board of Directors
GlaxoSmithKline -- one of the world's leading research-based
pharmaceutical and healthcare companies -- is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer. For company information, visit GlaxoSmithKline on the World Wide
Web at http://www.gsk.com.
SOURCE GlaxoSmithKline
 back to top
Related links:
http://www.gsk.com
http://www.prnewswire.com/comp/801350.html /
CONTACT:
US Media inquiries: Nancy Pekarek,
+1-215-751-7709, or Mary Anne Rhyne, +1-919-483-2839; UK Media
inquiries: Phil Thomson, +(020) 8047 5502, Alice Hunt, +(020)
8047 5502, or Gwenan White, +(020) 8047 5502; US Analyst -
Investor inquiries: Frank Murdolo, +1-215-751-7002, or Tom Curry,
+1-215-751-5419; European Analyst - Investor inquiries: David
Mawdsley, +(020) 8047 5564, Sally Ferguson, +(020) 8047 5543, or
Gary Davies, +(020) 8047 5503, all of GlaxoSmithKline
|
